Effect of hyperthermia on improving neutrophil restoration after intraperitoneal chemotherapy

References

• Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–E386.
   PubMed Web of Science ®Google Scholar
• De Angelis R, Sant M, Coleman MP, et al. Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE–5-a population-based study. Lancet Oncol. 2014;15(1):23–34.
   PubMed Web of Science ®Google Scholar
• Allemani C, Weir HK, Carreira H, et al. Global surveillance of cancer survival 1995–2009: analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet (London, England). 2015;385(9972):977–1010.
   PubMed Web of Science ®Google Scholar
• Armstrong DK, Bundy B, Wenzel L, for the Gynecologic Oncology Group, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354(1):34.
   PubMed Web of Science ®Google Scholar
• Walker JL, Armstrong DK, Huang HQ, et al. Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study. Gynecol Oncol. 2006;100(1):27–32.
   PubMed Web of Science ®Google Scholar
• Jaaback K, Johnson N, Lawrie TA. Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. Cochrane Database Syst Rev. 2016. 11:CD005340.
   Google Scholar
• De Bree E, Rosing H, Filis D, et al. Cytoreductive surgery and intraoperative hyperthermic intraperitoneal chemotherapy with paclitaxel: a clinical and pharmacokinetic study. Ann Surg Oncol. 2008;15(4):1183–1192.
   PubMed Web of Science ®Google Scholar
• Neuwirth MG, Alexander HR, Karakousis GC. Then and now: cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC), a historical perspective. J Gastrointest Oncol. 2016;7(1):18–28.
   PubMed Web of Science ®Google Scholar
• Markman M. Intraperitoneal chemotherapy in the management of malignant disease. Expert Rev Anticancer Therapy. 2001;1(1):142–148.
   PubMedGoogle Scholar
• El-Kareh AW, Secomb TW. A theoretical model for intraperitoneal delivery of cisplatin and the effect of hyperthermia on drug penetration distance. Neoplasia. 2004;6(2):117–127.
   PubMed Web of Science ®Google Scholar
• Steuperaert M, Debbaut C, Segers P, et al. Modelling drug transport during intraperitoneal chemotherapy. Pleura Peritoneum. 2017;2(2):73–83.
   PubMed Web of Science ®Google Scholar
• Cascales-Campos P, Gil J, Feliciangeli E, et al. HIPEC in ovarian cancer: treatment of a new era or is it the end of the pipeline? Gynecol Oncol. 2015;139(2):363–368.
   PubMed Web of Science ®Google Scholar
• Halkia E, Spiliotis J. The role of cytoreductive surgery and HIPEC in epithelial ovarian cancer. J Buon. 2015;20 (Suppl 1):S12–S28.
   PubMedGoogle Scholar
• Roviello F, Pinto E, Corso G, et al. Safety and potential benefit of hyperthermic intraperitoneal chemotherapy (HIPEC) in peritoneal carcinomatosis from primary or recurrent ovarian cancer. J Surg Oncol. 2010;102(6):663–670.
   PubMed Web of Science ®Google Scholar
• Cascales-Campos PA, Gil J, Gil E, et al. Treatment of microscopic disease with hyperthermic intraoperative intraperitoneal chemotherapy after complete cytoreduction improves disease-free survival in patients with stage IIIC/IV ovarian cancer. Ann Surg Oncol. 2014;21(7):2383–2389.
   PubMed Web of Science ®Google Scholar
• Bhatt A, Glehen O. The role of cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in ovarian cancer: a review. Indian J Surg Oncol. 2016;7(2):188–197.
   PubMed Web of Science ®Google Scholar
• Hotouras A, Desai D, Bhan C, et al. Heated IntraPEritoneal Chemotherapy (HIPEC) for patients with recurrent ovarian cancer: a systematic literature review. Int J Gynecol Cancer. 2016;26(4):661–670.
   PubMed Web of Science ®Google Scholar
• Van Driel WJ, Koole SN, Sikorska K, et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. New Engl J Med. 2018;378:230–240.
   PubMed Web of Science ®Google Scholar
• Huo YR, Richards A, Liauw W, et al. Hyperthermic intraperitoneal chemotherapy (HIPEC) and cytoreductive surgery (CRS) in ovarian cancer: a systematic review and meta-analysis. Eur J Surg Oncol. 2015;41(12):1578–1589.
   PubMed Web of Science ®Google Scholar
• Votanopoulos K, Ihemelandu C, Shen P, et al. A comparison of hematologic toxicity profiles after heated intraperitoneal chemotherapy with oxaliplatin and mitomycin C. J Surg Res. 2013;179(1):e133–e139.
   PubMed Web of Science ®Google Scholar
• Wu CC, Chuang YT, Hsu YT, et al. Intra-peritoneal hyperthermia combining alpha-galactosylceramide in the treatment of ovarian cancer. PLoS One. 2013;8(7):e69336.
   PubMed Web of Science ®Google Scholar
• Srivastava P. Interaction of heat shock proteins with peptides and antigen presenting cells: chaperoning of the innate and adaptive immune responses. Annu Rev Immunol. 2002;20(1):395–425.
   PubMed Web of Science ®Google Scholar
• Singh IS, Hasday JD. Fever, hyperthermia and the heat shock response. Int J Hyperthermia. 2013;29(5):423–435.
   PubMed Web of Science ®Google Scholar
• Moloney TC, Hoban DB, Barry FP, et al. Kinetics of thermally induced heat shock protein 27 and 70 expression by bone marrow-derived mesenchymal stem cells. Protein Sci. 2012;21(6):904–909.
   PubMed Web of Science ®Google Scholar
• Ellis GS, Carlson DE, Hester L, et al. G-CSF, but not corticosterone, mediates circulating neutrophilia induced by febrile-range hyperthermia. J Appl Physiol. 2005;98(5):1799–1804.
   PubMed Web of Science ®Google Scholar
• Nagarsekar A, Hasday JD, Singh IS. CXC chemokines: a new family of heat-shock proteins? Immunol Investig. 2005;34(3):381–398.
   PubMed Web of Science ®Google Scholar
• Rice P, Martin E, He JR, et al. Febrile-range hyperthermia augments neutrophil accumulation and enhances lung injury in experimental gram-negative bacterial pneumonia. J Immunol. 2005;174(6):3676–3685.
   PubMed Web of Science ®Google Scholar
• Tulapurkar ME, Hasday JD, Singh IS. Prolonged exposure to hyperthermic stress augments neutrophil recruitment to lung during the post-exposure recovery period. Int J Hyperthermia. 2011;27(7):717–725.
   PubMed Web of Science ®Google Scholar
• Clark OA, Lyman G, Castro AA, et al. Colony stimulating factors for chemotherapy induced febrile neutropenia. Cochrane Database Syst Rev. 2003;10:Cd003039.
   Google Scholar
• Sadik CD, Kim ND, Luster AD. Neutrophils cascading their way to inflammation. Trends Immunol. 2011;32(10):452–460.
   PubMed Web of Science ®Google Scholar
• De Filippo K, Dudeck A, Hasenberg M, et al. Mast cell and macrophage chemokines CXCL1/CXCL2 control the early stage of neutrophil recruitment during tissue inflammation. Blood. 2013;121(24):4930–4937.
   PubMed Web of Science ®Google Scholar
• Shen L, Smith JM, Shen Z, et al. Inhibition of human neutrophil degranulation by transforming growth factor-β1. Clin Exp Immunol. 2007;149:155–161.
   PubMed Web of Science ®Google Scholar
• Allen SS, Mackie JT, Russell K, et al. Altered inflammatory responses following transforming growth factor-β neutralization in experimental guinea pig tuberculous pleurisy. Tuberculosis. 2008;88(5):430–436.
   PubMed Web of Science ®Google Scholar
• Fridlender ZG, Sun J, Kim S, et al. Polarization of tumor-associated neutrophil phenotype by TGF-beta: “N1” versus “N2” TAN. Cancer Cell. 2009;16(3):183–194.
   PubMed Web of Science ®Google Scholar
• Farhood B, Najafi M, Mortezaee K. CD8+ cytotoxic T lymphocytes in cancer immunotherapy: a review. J Cell Physiol. 2019;234(6):8509–8521.
   PubMed Web of Science ®Google Scholar
• Wculek SK, Cueto FJ, Mujal AM, et al. Dendritic cells in cancer immunology and immunotherapy. Nat Rev Immunol. 2019. DOI:10.1038/s41577-019-0210-z
   PubMedGoogle Scholar
• Murshid A, Gong J, Calderwood SK. The role of heat shock proteins in antigen cross presentation. Front Immunol. 2012;3:63.
   PubMed Web of Science ®Google Scholar
• Thomas E, Dudar R. Differential response of normal and tumor microcirculation to hyperthermia. Cancer Res. 1984;44:605–612.
   PubMed Web of Science ®Google Scholar
• Glehen O, Cotte E, Kusamura S, et al. Hyperthermic intraperitoneal chemotherapy: nomenclature and modalities of perfusion. J Surg Oncol. 2008;98(4):242–246.
   PubMed Web of Science ®Google Scholar
• Coccolini F, Corbella D, Finazzi P, et al. Time course of cytokines, hemodynamic and metabolic parameters during hyperthermic intraperitoneal chemotherapy. Minerva Anestesiol. 2016;82(3):310–319.
   PubMed Web of Science ®Google Scholar
• Boettcher S, Manz MG. Regulation of inflammation- and infection-driven hematopoiesis. Trends Immunol. 2017;38(5):345–357.
   PubMed Web of Science ®Google Scholar
• Mulier S, Claes JP, Dierieck V, et al. Survival benefit of adding Hyperthermic IntraPEritoneal Chemotherapy (HIPEC) at the different time-points of treatment of ovarian cancer: review of evidence. Curr Pharm Des. 2012;18(25):3793–3803.
   PubMed Web of Science ®Google Scholar